+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 79 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating a combination therapy of ruxolitinib, steroids, and lenalidomide in adults with relapsed or refractory multiple myeloma MM who have progressive disease despite previous treatments. MM is a cancer of plasma cells in the bone marrow with complex causes and limited curative options. This phase 1, open-label, multicenter study aims to assess the safety and effectiveness of these drugs together in patients who have failed at least two prior therapies including immunomodulatory drugs and proteasome inhibitors. Participants receive varying doses of ruxolitinib orally twice daily, lenalidomide once daily, and methylprednisolone every other day. The study includes dose escalation periods and treatment adjustments based on disease progression. Some groups start with ruxolitinib and steroids, adding lenalidomide only if the disease worsens. Treatment continues until disease progression or unacceptable side effects occur. During the study, participants will have regular evaluations including blood tests and clinical assessments to monitor safety, side effects, and treatment response. Researchers will measure outcomes such as the maximum tolerated dose, adverse events, response rates, progression-free and overall survival over a follow-up period extending up to 54 months. Participants are expected to adhere to visit schedules and study requirements throughout the trial.

Age: 18Years +All GendersPhase 1
13 locations
R

Actively Recruiting

Researchers are evaluating BNT324 compared to the standard chemotherapy docetaxel combined with prednisone or prednisolone in men with metastatic castration-resistant prostate cancer mCRPC who have been previously treated with androgen receptor pathway inhibitors but have not received taxane-based chemotherapy for mCRPC. This phase III trial aims to determine if BNT324 can help participants live longer without their cancer worsening and improve overall survival. Participants are randomly assigned to one of two groups receiving BNT324 through intravenous infusion or receiving docetaxel intravenously along with oral prednisone or prednisolone. Treatment is given in 21-day cycles and continues until the cancer progresses, side effects become unacceptable, the participant decides to stop, or the study concludes. The study includes a screening period lasting up to 28 days, followed by treatment and an after-treatment period that includes a 30-day safety follow-up and a long-term survival follow-up. Participants will undergo assessments including scans reviewed centrally to monitor cancer progression, laboratory tests such as PSA levels, and evaluation of side effects. Researchers will track outcomes like radiographic progression-free survival and overall survival for up to approximately 58 months. Safety is closely monitored by an independent committee, and participants continue regular follow-up visits during and after treatment to assess response and manage any adverse events.

Age: 18Years +MALEPhase 3
52 locations
C

Actively Recruiting

Researchers are comparing two treatment combinations for adults with advanced nonsquamous non-small cell lung cancer NSCLC that is stage IV or advanced stage IIIBC, specifically with a KRAS p.G12C mutation and no PD-L1 expression. The study evaluates progression-free survival and overall survival between participants receiving sotorasib with chemotherapy and those receiving pembrolizumab with chemotherapy. This is a phase 3, randomized, open-label study aiming to find which frontline therapy might better manage this type of lung cancer. Participants are randomly assigned to one of two groups one group receives sotorasib orally combined with carboplatin and pemetrexed chemotherapy, and the other group receives pembrolizumab given intravenously combined with the same chemotherapy agents. Treatments are given as front-line therapy for their cancer. The study measures the effects of these combinations over time, including tumor response and quality of life changes. During the study, participants will be closely monitored for progression-free survival, overall survival, and other outcomes related to tumor response and quality of life through questionnaires. Researchers will track treatment-emergent adverse events, vital signs, and lab tests to evaluate safety. The study includes follow-up assessments for up to approximately 5.5 years, allowing comprehensive evaluation of long-term outcomes and side effects. Participant involvement includes regular visits for treatment administration and assessments throughout the study period.

Age: 18Years - 100YearsAll GendersPhase 3
424 locations
S

Actively Recruiting

Researchers are evaluating how well amivantamab combined with lazertinib or with chemotherapy works in treating participants with epidermal growth factor receptor mutated EGFRm non-small cell lung cancer NSCLC, a common type of lung cancer. This Phase 2b study focuses on patients whose NSCLC is locally advanced or metastatic and who have specific EGFR mutations. The study aims to assess antitumor activity and treatment effects over time. Participants are assigned to one of two treatment groups. One group receives subcutaneous amivantamab combined with oral lazertinib in 28-day cycles, and the other group receives subcutaneous amivantamab combined with intravenous platinum-based chemotherapy carboplatin and pemetrexed in 21-day cycles. Treatment continues until disease progression, withdrawal, death, or investigator decision. The study is open-label and non-randomized, consisting of two parallel cohorts. During the study, participants will undergo regular assessments to monitor tumor response and safety. Key measures include progression-free survival tracked for up to 4 years and 6 months, along with evaluations of adverse events, overall survival, response rates, and duration of response. Researchers will also monitor dose changes and specific side effects such as venous thromboembolic events and dermatologic reactions. Participation may last several years depending on individual treatment and disease course.

Age: 18Years +All GendersPhase 2
205 locations
E

Actively Recruiting

Researchers are studying ART0380, an investigational oral drug that targets ATR kinase, in people with advanced or metastatic solid tumors, including ovarian, peritoneal, fallopian tube, endometrial, colorectal, pancreatic, and acinar cell cancers. This open-label Phase IIIa trial aims to find the recommended dose of ART0380 alone and in combination with gemcitabine or irinotecan, to understand its side effects, and to evaluate its preliminary effectiveness in treating cancers that may have DNA repair defects or loss of ATM protein expression. Participants may receive ART0380 either alone or combined with gemcitabine or irinotecan in 21-day treatment cycles. ART0380 is given orally either intermittently or continuously, while gemcitabine is given on days 1 and 8, and irinotecan is infused on days 1 and 8 of each cycle. The study has multiple parts, including dose escalation phases and expansion cohorts targeting specific cancer types or genetic profiles. Some parts compare ART0380 plus gemcitabine to gemcitabine alone, while others explore ART0380 with irinotecan or as monotherapy. Throughout the study, participants will undergo regular assessments including imaging scans to evaluate tumor response by RECIST criteria, blood tests for tumor markers, and safety monitoring for side effects. Pharmacokinetics of ART0380 will be measured to understand drug levels and metabolism. Follow-up for progression-free survival and overall survival will continue for up to two years or more. Participants are expected to adhere to study visits and procedures, with performance status and organ function closely monitored during the trial.

Age: 18Years +All GendersPhase 1Phase 2
88 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of azenosertib ZN-c3, an oral selective WEE1 inhibitor, in women with platinum-resistant, high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. This Phase 2 study focuses on patients whose tumors express Cyclin E1 protein, identified through a specialized assay. The study includes multiple parts, with Part 2 specifically enrolling Cyclin E1 positive patients to better understand the drugs impact in this subgroup. Participants receive azenosertib orally, following an intermittent dosing schedule of 400 mg once daily for 5 days, then 2 days off. Different dosing arms exist, including a 300 mg dose, all administered under careful monitoring. The study is randomized and open-label, with several parts completed and Part 2c actively enrolling. The treatment period and follow-up extend for up to approximately 12 months to assess various outcomes. During the study, participants undergo tumor testing, disease evaluation by standard imaging criteria RECIST v1.1, and monitoring of blood markers such as CA-125. Researchers track response rates, duration of response, progression-free survival, clinical benefit, and adverse events. Regular assessments ensure safety and treatment adherence. The total participation duration encompasses treatment and follow-up phases, with outcomes measured up to about one year after the last participant enrolls.

Age: 18Years +FEMALEPhase 2
89 locations
P

Actively Recruiting

Researchers are evaluating whether baricitinib can delay the onset of clinical type 1 diabetes T1D in children and adults who are at high risk of developing this condition. This Phase 3, double-blind, randomized, placebo-controlled study includes participants aged 1 to less than 36 years with early-stage type 1 diabetes or specific diabetes-related autoantibodies. The study is sponsored by Eli Lilly and Company and aims to understand if baricitinib can postpone progression to stage 3 T1D. Participants will be randomly assigned to receive either baricitinib or a placebo orally. The intervention period may last up to approximately 5 years, during which the time from baseline to diagnosis of stage 3 type 1 diabetes will be closely monitored. Both groups will be followed to assess changes in glucose metabolism, C-peptide levels, body measurements, and quality of life. During the study, participants will undergo regular assessments including blood tests to measure glucose-stimulated C-peptide, glucose levels, and other metabolic markers at baseline and after one year. Additional evaluations include body height, body mass index percentile, and health surveys. Pharmacokinetics of baricitinib will also be monitored up to week 24. Safety and efficacy data will be collected throughout the study period, lasting up to approximately 5 years per participant.

Age: 1Year - 35YearsAll GendersPhase 3
112 locations
O

Actively Recruiting

Researchers are evaluating the safety and tolerability of inhaled mosliciguat in participants with pulmonary hypertension linked to interstitial lung disease PH-ILD. This Phase 2, open-label, multi-center study involves participants already using inhaled treprostinil, aiming to assess mosliciguat when added to this background treatment. The study is sponsored by Pulmovant, Inc. and focuses on treatment safety in this specific lung condition. Participants will receive inhaled mosliciguat daily during a 16-week open-label treatment period. After completing this initial phase, participants may continue into an extension period where mosliciguat treatment continues beyond 16 weeks. The drug is delivered via a dry powder inhaler, with dose levels adjusted for inhalation as part of the study. During the study, participants will be monitored for adverse events and tolerability of the treatment at baseline and at week 16. Assessments include clinical evaluations and safety monitoring throughout both the initial treatment and extension periods. The total study duration extends until January 2028, allowing for long-term observation of treatment effects and participant health outcomes.

Age: 18Years - 85YearsAll GendersPhase 2
13 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of neoadjuvant carboplatin combined with mirvetuximab soravtansine in adult women with advanced-stage serous epithelial ovarian, fallopian tube, or primary peritoneal cancer that expresses folate receptor alpha FR. This phase 2, single-arm study focuses on patients with stage III or IV disease confirmed by specific diagnostic criteria. Mirvetuximab soravtansine is an investigational antibody drug conjugate designed to selectively target and kill cancer cells expressing FR. Participants receive intravenous infusions of mirvetuximab soravtansine together with carboplatin on day 1 of each 21-day cycle, for up to 6 to 9 cycles. Bevacizumab may also be given at the investigators discretion. The treatment is provided in a hospital or clinic setting. The total study duration, including treatment and follow-up, is approximately three years. During the study, participants attend regular visits for medical assessments, blood tests, and imaging scans to monitor their condition and treatment response. Researchers will evaluate the objective response to treatment by independent central review and investigator assessments, as well as safety through adverse event monitoring. Additional measures include progression-free survival, disease control, symptom changes, and surgery outcomes. The study aims to understand how well the treatment works and its safety profile over the course of the trial.

Age: 18Years +FEMALEPhase 2
73 locations
C

Actively Recruiting

Researchers are investigating treatments for newly diagnosed acute myeloid leukemia AML in children and young adults, with or without mutations in the FLT3 gene. This Phase III trial compares standard chemotherapy, which includes daunorubicin, cytarabine, and gemtuzumab ozogamicin, to therapy using a special formulation called CPX-351, which contains daunorubicin and cytarabine designed to stay longer in the bone marrow. The study also evaluates adding gilteritinib, a drug that may block abnormal FLT3 gene function and slow cancer growth, especially in patients with FLT3 mutations. The goals include comparing treatment effects, studying heart function during therapy, and assessing neurocognitive outcomes. Participants receive treatment based on risk groups and FLT3 mutation status, assigned to different study arms. Treatments include various combinations of chemotherapy drugs given intravenously, intrathecally, or orally, such as CPX-351, daunorubicin, cytarabine, gemtuzumab ozogamicin, dexrazoxane, etoposide, mitoxantrone, and gilteritinib. Treatment phases include induction, intensification, and for some, hematopoietic stem cell transplantation HSCT. Intrathecal therapies address central nervous system involvement. Gilteritinib is administered orally over extended periods in certain groups. The study also involves optional neurocognitive testing. Throughout the study, participants undergo regular assessments including blood and bone marrow samples, imaging scans like MRI and PET, and cardiac function tests such as echocardiograms. Researchers monitor minimal residual disease, survival rates, heart health, and neuropsychological function. Safety and adverse events are tracked up to three years, with some patients receiving long-term gilteritinib maintenance. The overall participation may last several years, allowing detailed evaluation of treatment impact and side effects.

Age: 6Months - 21YearsAll GendersPhase 3
206 locations

1-10 of 79

1